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Immune reconstitution inflammatory syndrome; Meningoencephalitis myelitis; Mycobacterium avium complex Disseminated Mycobacterium avium complex (MAC) infection involves the central nervous system (CNS) less frequently than tuberculosis, and MAC-related immune reconstitution inflammatory syndrome (IRIS) of the CNS in AIDS patients is even more rarely described. We report a case of MAC-related IRIS of the CNS in an HIV-infected patient who presented with meningoencephalitis and myelitis 2 months after discontinuation of antiMAC therapy, when he had achieved prolonged suppression of HIV replication and restoration of CD4 counts to >100 cells/mL for 1 year. Cases of MAC-related IRIS of the CNS reported in the literature are reviewed. Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Introduction
Disseminated Mycobacterium avium complex (MAC) infection, an important AIDS-defining opportunistic infection commonly occurring in patients with CD4 lymphocyte counts <50 cells/mL, is associated with significant morbidity and mortality, and with shortened survival.
1,2
With the introduction of highly active antiretroviral therapy (HAART) in 1996, the incidences of opportunistic infections, including disseminated MAC (DMAC) infection, and AIDS-related mortality and hospitalization dramatically declined in HIV-infected patients. 3 The beneficial effects of HAART result from gradual restoration of pathogen-specific immune responses, mediated by suppression of HIV-1 replication and increases of CD4 counts.
4,5 However, adverse clinical phenomena, including paradoxical worsening of treated opportunistic infections or unmasking of previously subclinical untreated infections, may develop during the initial months, or even years 6 of HAART. These atypical presentations have since been recognized as inflammatory reactions directed at quiescent opportunistic pathogens following CD4 increases with HAART, otherwise known as immune reconstitution inflammatory syndrome (IRIS). MAC-related IRIS most commonly presents as focal lymphadenitis without mycobacteremia, with or without suppuration.
7e10 Cerebral MAC infection is very uncommon, and MAC-related IRIS of the central nervous system (CNS) is even rarer.
11,12 Herein, we present a case of an HIV-1 infected patient who developed an unusual and potentially devastating meningoencephalitis and myelitis due to MAC infection almost 17 months after commencing effective HAART and one year after attaining a sustained rise of CD4 cell count >100 cells/mL. Reported cases of MACrelated IRIS of the CNS in the literature are reviewed with the aim of better understanding of the rare form of IRIS associated with DMAC infection.
Case report
The 23-year-old homosexual man with HIV infection who was diagnosed in 2006 presented with intermittent fevers and oral candidiasis. HAART was prescribed in April 2008 but he did not continue this treatment due to severe nausea and vomiting. He began to have abdominal fullness, weight loss and intermittent fevers since August 2008 and computed tomography of the abdomen disclosed prominent ascites, marked splenomegaly and multiple confluent enlarged lymphadenopathies in the retroperitoneum and para-aortic regions in October 2008. Excisional biopsy of the inguinal lymph node only revealed histiocytosis. Progressive abdominal distension and dyspnea developed later and chest radiography showed massive left pleural effusion. The CD4 count was 2 cells/mL, and the plasma HIV RNA load (PVL) 77600 copies/mL in November 2008. After admission, HAART with abacavir/lamivudine and lopinavir/ ritonavir was initiated and antiMAC therapy was begun with moxifloxacin, amikacin, clarithromycin and ethambutol when MAC was isolated from cultures of pleural effusion, lung biopsy, blood, ascites, bone marrow, and stool specimens. In the following months, the patient had been well and PVL was <50 copies/mL and a CD4 count >100 cells/mL on several occasions for more than one year. Given the clinical stability of the patient after about 14 months of antiMAC therapy and his significant immunological response to HAART, antiMAC therapy was discontinued in February 2010.
In April 2010, the patient presented with a one-week history of low back pain, easily stumbling, and progressive paraplegia. The physical examination revealed an illlooking man who was afebrile, drowsy, and had neck stiffness and a decrease in muscle power of the bilateral lower extremities. Laboratory investigations showed a CD4 count of 70 cells/mL, PVL<50 copies/mL and a serum cryptococcal antigen titer of <1:2; the remainders were otherwise normal. A magnetic resonance imaging disclosed numerous tiny enhancing nodules diffusely scattered in the bilateral cerebral and cerebellar hemispheres, deep gray matter, brain stem and whole spinal cord (Fig. 1) . A lumbar puncture revealed opening pressure, 230 mmH 2 O; white cells, 6/mL (L/N, 6/0); protein, 141 mg/dL; and glucose, 32 mg/ dL. Under the tentative diagnosis of MAC meningoencephalitis and myelitis, levofloxacin, clarithromycin, ethambutol and rifabutin were resumed. Adjunctive dexamethasone was added at a dose of 4 mg before antiMAC therapy was given with subsequent daily dose of 16 mg. After 5 days of therapy, the patient's consciousness totally recovered and muscle power significantly improved. A second lumbar puncture showed opening pressure, 52 mmH 2 O; white cell, 0; protein, 48 mg/dL; and glucose, 58 mg/dL. MAC was subsequently cultured from both blood and cerebrospinal fluid specimens and he was discharged well on the 29th hospital day. The patient remained stable on the antiMAC therapy after discharge.
Discussion
In the present case, the patient initially presented with DMAC infection with mycobacteremia, pneumonia, empyema, and peritonitis. After commencing HAART and continuation of antimycobacterial regimen, good virological response and gradual restoration of immune function were observed. According to the guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents 13 antiMAC therapy that had been given for 14 months with satisfactory resolution of symptoms in our case was ceased after the patient fulfilled the criteria for discontinuing secondary prophylaxis of DMAC infection. However, new onset of neurological symptoms and signs occurred 2 months after ceasing antiMAC therapy despite adequate immunity, which is consistent with a diagnosis of MAC-related CNS-IRIS.
Diagnosis of IRIS of the CNS is difficult because IRIS remains a clinical syndrome with variable presentations and severities, and pathologic and microbiologic investigations of the CNS involvement are limited by potential morbidity related to the diagnostic procedures. According to clinical features defined by Riedel and colleagues 14 our patient fulfills his working definition, except without confirmation by histopathology that may demonstrate T-cell infiltration. Our arguments for MAC-related CNS-IRIS in this case are as follows. First, the immune reconstitution was documented by a sustained increase in CD4 count >100 cells/mL for one year, a level at which DMAC disease would be less likely to occur in HIV-infected patients. Second, our patient had risk factors for the development of IRIS, which include a high baseline PVL and a lower baseline CD4 count before initiation of HAART, rapid decline in PVL after HAART, a high antigenic burden and disseminated infection, initiation of HAART concurrently with or soon after initiation of antimicrobial therapy of an acute infection, and being antiretroviral-naïve. 15 Although MAC could be cultured from affected tissue, French et al 16 and Shelburne et al 17 do not consider mycobacteremia as criteria of exclusion for MACrelated IRIS.
Typically most cases of mycobacteria-associated CNS-IRIS occur within 5 to 10 months after HAART is commenced. 18e20 The present case of MAC-related CNS-IRIS is unique because of its late development after HAART, and because of the CNS localization. MAC-associated CNS-IRIS in HIV-infected patients is rare and a search of the PubMed database (English language publications) identified four reported cases of CNS infection related to IRIS due to MAC infection in patients with AIDS.
12,21e23 The clinical presentations and relationship to timing of HAART of the five cases (including the present case) are shown in Table 1. 12,21e23 All reported cases were male and the median age of the patients was 36 years (range, 24e51 years). The presenting neurological symptoms included headache (2 patients), visual disturbance (1), aphasia (1), disorientation (1), drowsy consciousness (2), and paraplegia (1). The image study of the brain demonstrated hypodensities or ringenhancing lesions of varying size. Manifestations of IRIS developed after a median of 17 months of HAART (range, 2e25 months). Patients had a median CD4 count of 20 cells/ mL (range, 2e80 cells/mL) at baseline and a median plasma HIV viral load of 7.8 Â 10 4 copies/mL (range, 1.4 Â 10 4 e3.9 Â 10 5 copies/mL) before beginning HAART. At the time IRIS was diagnosed, the CD4 count had increased to a median of 70 cells/mL (range, 10e210 cells/mL) and the PVL had decreased to below the lower limit of detection in all of the patients. MAC was isolated from affected tissue in four of the five patients and only our patient had documented mycobacteremia. Corticosteroids were prescribed in addition to antimycobacterial drugs in two patients and all-cause mortality rate was 40% (2/5).
MAC-related IRIS may be clinically indistinguishable from active infection, and is mostly benign and self-limiting; however, severe cases and death have been described. 23 Optimal management of the various presentations of MACrelated IRIS of the CNS remains poorly defined because there are no well-conducted randomized treatment trials for these complications related to HAART. Generally, continuation of HAART is recommended and most deteriorating conditions will improve gradually. Use of corticosteroids does not yet document a mortality benefit but is indicated for catastrophic CNS-IRIS in patients who have massive inflammation, resulting in impending brain herniation. 24 In our patient, rapid improvement of neurological symptoms after addition of steroids was observed (about 5 days), which suggests the disease entity as fulminant inflammation involving the CNS, instead of relapsing infection.
The reported incidence of relapsing MAC disease in HIVinfected patients receiving HAART after the interruption of maintenance therapy is very low 25 and relapses are often observed in patients who fail to respond to, or stop, HAART other than to MAC-IRIS. There are well-known guidelines that recommend when to discontinue primary and secondary prophylaxis for several opportunistic infections in AIDS patients with HAART-related immune reconstitution. 13 In the present case, antimycobacterial regimens were discontinued when CD4 count had increased to the recommended cut-off value for discontinuation of prophylaxis for MAC infection, although MAC-associated IRIS of the CNS developed. Therefore, clinicians must always be more cautious when stopping maintenance therapy for MAC disease and remain alert for atypical presentations. Given the potentially devastating consequences of such an immune reconstitution, we should understand this disease entity more, even if the overall occurrence of MAC disease is still rare after ceasing secondary prophylaxis in HIVinfected patients with good response to HAART. 
